Balancing Harms and Benefits in Bioethics

Every medical decision, at its core, involves a trade-off. A chemotherapy drug that fights cancer also damages healthy cells. A surgery that saves a life carries the risk of complications. A clinical trial that advances medical knowledge exposes participants to uncertain outcomes. These are not failures of medicine – they are the inherent tensions that make bioethics necessary. The challenge is not to eliminate harm entirely, which is often impossible, but to ensure that the benefits of any healthcare action genuinely and justifiably outweigh its costs. This is the central task of the bioethical principle of minimizing harms while maximizing benefits.

The utilitarian foundation: greatest good for the greatest number 🔗

The idea of maximizing benefits while minimizing harms draws directly from utilitarianism, the ethical theory associated with philosophers Jeremy Bentham and John Stuart Mill. In utilitarian thinking, an action is morally right when it produces the greatest overall good – maximizing well-being and minimizing suffering across all those affected. Applied to healthcare, this translates into a guiding logic: medical interventions should aim to produce the most favorable outcomes for the most people, while keeping adverse effects as low as possible.

In practice, this consequentialist reasoning shapes much of how healthcare systems allocate resources, design treatment protocols, and evaluate interventions. As bioethicists note, in the utilitarian approach decisions are chosen based on achieving the greatest amount of benefit for the greatest number of individuals – an approach that is outcome-oriented and deeply focused on results. However, this approach is not without its complications, as it can sometimes conflict with the rights and dignity of individuals when population-level goals take precedence.

Act utilitarianism vs. rule utilitarianism in medicine 🔗

There are two important variants of utilitarianism that play out differently in clinical settings. Act utilitarianism requires weighing the costs and benefits fresh for each individual case, making a judgment specific to that patient and situation. This is responsive and flexible but can be time-consuming and prone to bias. Rule utilitarianism, by contrast, relies on pre-established guidelines derived from evidence – rules designed to produce better outcomes overall when consistently applied. According to research published in PMC, rule utilitarianism provides better guidance than act utilitarianism in clinical decision-making because these rules are grounded in evidence and reduce the subjectivity of individual judgments. Most clinical protocols, treatment guidelines, and triage systems operate on a rule utilitarian basis.

The four principles of biomedical ethics 🔗

In 1979, philosophers Tom Beauchamp and James Childress published Principles of Biomedical Ethics, which became the foundational text of modern bioethical reasoning. The University of Washington’s Department of Bioethics & Humanities notes that Beauchamp and Childress popularized what is now known as principlism – an approach that organizes ethical reasoning around four core principles: respect for autonomy, beneficence, non-maleficence, and justice. The interplay between these principles is at the heart of every harm-benefit analysis in healthcare.

Beneficence: the duty to do good 🔗

Beneficence is the obligation to act in ways that benefit patients and advance their well-being. According to the UK Clinical Ethics Network, the principle of beneficence requires healthcare professionals to weigh carefully how to balance the benefits of treatment against any risks and costs involved. This goes beyond simply providing treatment – it requires thinking about what genuinely serves the patient’s interest, considering their values, quality of life preferences, and risk tolerance.

Beauchamp and Childress identify two aspects of beneficence: positive beneficence, which means actively providing benefits to others, and utility, which means balancing benefits, risks, and costs to achieve the best overall result. Together, they call on healthcare professionals to not only avoid causing harm but to strive actively for good outcomes.

Non-maleficence: first, do no harm 🔗

Non-maleficence is the principle that healthcare professionals must refrain from actions that cause unnecessary harm to patients. It is rooted in the Hippocratic maxim primum non nocere – “first, do no harm.” As the UK Clinical Ethics Network explains, all treatment is likely to involve some degree of harm, even if minimal, but that harm must not be disproportionate to the benefits of the treatment.

Non-maleficence and beneficence work in tandem. As Beauchamp and Childress note, non-maleficence sets a minimal standard – whatever you do for your patients, at least do not harm them – while beneficence sets a higher standard by calling on medical personnel to maximize benefits and prioritize well-being. Together, these two principles capture the full obligation to act for the overall benefit of the patient.

The role of autonomy and justice 🔗

Autonomy refers to the patient’s right to make informed decisions about their own care. In the context of harm-benefit analysis, respecting autonomy means ensuring that patients understand the potential risks and benefits of any proposed treatment before consenting to it. As bioethics research in PMC affirms, effective communication between physician and patient, grounded in the ethical standards of informed consent, is an essential prerequisite for achieving full and conscious adherence to prescribed treatments.

Justice introduces the question of fairness – who receives the benefits of healthcare, and who bears its burdens? In harm-benefit calculations, justice demands that the distribution of risks and rewards be equitable. Voices in Bioethics cautions that relying exclusively on consequentialist reasoning, without the corrective of justice, can produce unforeseen harms and moral failure – particularly for vulnerable populations who may bear disproportionate risks.

The Belmont Report and the formalization of beneficence 🔗

The harm-benefit framework was formally codified in research ethics through the Belmont Report of 1979, which emerged in the aftermath of the Tuskegee syphilis study – a scandal in which Black men with syphilis were deliberately left untreated without their knowledge, in violation of every principle of ethical research. The Belmont Report established three foundational principles for research involving human subjects: respect for persons, beneficence, and justice. The principle of beneficence was specifically formulated around two general rules: do no harm, and maximize benefits while minimizing potential harms. This gave the harm-benefit principle formal regulatory authority, moving it from philosophical abstraction to institutional obligation.

Risk-benefit analysis in clinical practice 🔗

In everyday medical settings, the balance of harms and benefits is not a theoretical exercise – it is a practical judgment made constantly by clinicians. When a physician recommends chemotherapy for a cancer patient, they are weighing the severe short-term side effects against the long-term chance of remission. When a surgeon decides whether to operate, they consider procedural risks against the dangers of leaving a condition untreated. According to the National Bioethics Advisory Commission, beneficence in research requires that possible risks are minimized and that any risks remaining are justified by the potential benefits of the intervention.

Informed consent as the practical mechanism 🔗

One of the most critical tools for implementing the harm-benefit balance at the individual level is informed consent. Before a patient undergoes any treatment or participates in a clinical trial, they must be given comprehensive information about the potential benefits and risks involved. Research on informed consent in clinical settings confirms that information provided to patients should include the nature and purpose of the study, probable risks and benefits, available alternatives, and the right to withdraw at any time. The goal is to enable patients to make decisions that genuinely reflect their own values and circumstances.

However, informed consent is not without its challenges. Studies have found that standard measures for how informed consent documents should be written are often lacking, and that some practitioners provide consent forms that are too long or technically complex for patients to meaningfully understand – effectively compromising their ability to assess risks and benefits for themselves.

Clinical trials and the tension between individual and collective benefit 🔗

Clinical trials represent one of the sharpest points of tension in harm-benefit ethics. Phase 1 drug trials, for example, are designed to test for side effects and establish dosing parameters, often enrolling healthy individuals who will receive no direct medical benefit from participation. These participants take on real risk in service of future patients and broader medical progress. This is considered ethically permissible only when risks are minimized, participants give genuinely informed consent, and the potential societal benefits are significant enough to justify the exposure.

As the Cambridge Handbook of Health Research Regulation emphasizes, certain risks cannot be justified even when research has great scientific or social value – there are ethical limits on how much risk individuals can reasonably be asked to assume for the benefit of others, regardless of consent.

Utilitarianism under pressure: when maximizing the good falls short 🔗

A purely utilitarian approach to harm-benefit analysis has well-documented limitations. When the focus is exclusively on maximizing aggregate outcomes, the rights and dignity of individuals can be subordinated to broader statistical goals. Research on crisis healthcare ethics highlights how, during the COVID-19 pandemic, the postponement of non-urgent surgeries harmed individual patients – people with cancer delayed treatments, others endured pain – while those harms were justified on the grounds of protecting broader population health.

Scholars at Columbia’s Voices in Bioethics argue that utilitarianism must be supplemented by other ethical frameworks – particularly Kantian ethics, which insists that each human life holds intrinsic moral value and that individuals must not be treated merely as means to an end. A multi-principled framework that draws on both consequentialist and deontological reasoning offers a more balanced approach to harm-benefit analysis – one that keeps sight of both the population and the individual person within it.

Vulnerability and the obligation to protect 🔗

The harm-benefit principle carries special weight when dealing with vulnerable populations – patients facing terminal illness, children, people with cognitive impairments, or those participating in research in low-resource settings. As bioethics researchers note, an adequate conception of vulnerability must not be restricted to protecting against harm alone – it must also focus on maximizing the capacity of vulnerable individuals to benefit from research and medical care. This means strategic planning, sustained relationships, and active effort to ensure that the most at-risk patients are not simply shielded from participation but are genuinely supported in accessing its benefits.

In disaster triage – the system used in mass casualty events – utilitarian harm-benefit logic is made starkly visible. As Wikipedia’s entry on utilitarian bioethics explains, triage operates on the principle of doing the greatest good for the greatest number, sometimes forgoing treatment of those in critical conditions in favor of those with higher chances of recovery. It is one of the few widely accepted models in which explicit utilitarian calculus directly governs life-and-death decisions – and it illustrates both the power and the moral discomfort of pure outcome-based reasoning.

Balancing in practice: no formula, only judgment 🔗

What makes harm-benefit analysis genuinely difficult is that there is no universal formula. Beauchamp and Childress themselves acknowledge that their four principles are general guides that leave considerable room for judgment in individual cases, and that genuine ethical dilemmas arise when two principles conflict in ways that make it impossible to fully honor both simultaneously. When a patient’s autonomy conflicts with a clinician’s beneficence – when a patient refuses a treatment that the doctor believes is in their best interest – the tension is not resolved by a rule, but by careful, context-sensitive ethical reasoning.

This is precisely why bioethics exists as a discipline: not to eliminate moral uncertainty, but to provide frameworks, principles, and methods for navigating it thoughtfully. The goal is always the same – to ensure that the least possible harm is caused and the greatest possible good is achieved, for each patient and for the broader human community they belong to.

What do you think? When a healthcare system must choose between maximizing benefit for the many or protecting the rights of a single vulnerable individual, where should the ethical boundary lie? And is it ever truly possible to obtain “informed” consent when patients facing serious illness may be too distressed or too medically uninformed to fully evaluate the risks and benefits presented to them?

References

1. https://www.thepermanentejournal.org/doi/10.7812/TPP/18-030
2. https://pmc.ncbi.nlm.nih.gov/articles/PMC4778182/
3. https://depts.washington.edu/bhdept/ethics-medicine/bioethics-topics/articles/principles-bioethics
4. https://ukcen.org/guidance-for-clinical-ethics-services/ethical-frameworks/four-principles/
5. https://www.researchgate.net/publication/394157036_Beauchamp_and_Childress_Principles_of_Biomedical_Ethics
6. https://pmc.ncbi.nlm.nih.gov/articles/PMC12450993/
7. https://journals.library.columbia.edu/index.php/bioethics/article/view/6082
8. https://pmc.ncbi.nlm.nih.gov/articles/PMC9511940/
9. https://www.ncbi.nlm.nih.gov/books/NBK215888/
10. https://pmc.ncbi.nlm.nih.gov/articles/PMC3601699/
11. https://pmc.ncbi.nlm.nih.gov/articles/PMC12744489/
12. https://www.cambridge.org/core/books/cambridge-handbook-of-health-research-regulation/riskbenefit-analysis/5582ABF8A81BA89D6F72686B3929F0A2
13. https://pmc.ncbi.nlm.nih.gov/articles/PMC7809094/
14. https://en.wikipedia.org/wiki/Utilitarian_bioethics